Vancouver, British Columbia – TheNewswire – November 15, 2021 – Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) (the “Company” or “Lexston”) is pleased to announce that after successfully completing the application process, the Company has received approval from OTC Markets Group Inc. for its common shares to begin trading on the OTCQB Market ("OTCQB") beginning at market open on November 12, 2021 under the symbol "LEXTF". The Company’s common shares will remain listed on the CSE in Canada under the ticker symbol "LEXT".
OTC Markets Group Inc., located in New York, N.Y., operates the world’s largest electronic inter-dealer quotation system for broker dealers to trade over 10,000 securities. The OTCQB is a transparent trading platform that offers a cost-effective method for United States investors to access Lexston’s securities. Lexston’s quotation and trading on the OTCQB provides investors the opportunity to benefit from streamlined market standards which enhance the availability of information to the general public, enabling greater transparency. North American and international investors can find Real-Time level 2 quotes (denominated in US dollars) and market information for Lexston Life Sciences Corp. common shares at https://www.otcmarkets.com/stock/LEXTF/quote along with current company news.
The Company would like to thank Nikolaos Galanopoulos of Galanopoulos & Company, the corporate securities law firm that advised Lexston in relation to the OTCQB application process.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal, Chief Executive Officer
Telephone: (604) 928-8913
Forward Looking Information
Neither the CSE nor its regulations service providers accept responsibility for the adequacy or accuracy of this news release. This news release includes forward-looking information within the meaning of Canadian securities laws regarding Lexston their respective businesses. Such statements are based on the current expectations and views of future events of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including market conditions, economic factors, management’s ability to manage Lexston and the equity markets generally.
Although Lexston has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in the forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Lexston does not undertake any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events, or otherwise.
Copyright (c) 2021 TheNewswire – All rights reserved.
